Drug Trial Radar · NCT03759379
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
164
Actual
Start
Feb 14, 2019
Primary completion
Nov 10, 2020
Study completion Nov 5, 2025
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Nov 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in participants with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran subcutaneous (SC) injection once every 3 months (q3M) or the reference comparator patisiran intravenous (IV) injection once every 3 weeks (q3w) during the 18 month Treatment Period. This study will use the placebo arm of the APOLLO study (NCT01960348) as an external comparator for the primary and most other efficacy endpoints during the 18 Month Treatment Period. Following the 18 Month Treatment Period, all participants will be randomized to receive vutrisiran 50 mg SC injection once every 6 months (q6M) or vutrisiran 25 mg q3M in the Randomized Treatment Extension (RTE) Period. Upon implementation of Amendment 6, participants receiving vutrisiran SC 50 mg q6M will transition to vutrisiran SC 25 mg q3M at their next scheduled dosing.
Conditions
- Amyloidosis, Hereditary
- Transthyretin Amyloidosis
Interventions
PatisiranDrug
Patisiran will be administered by IV infusion.
VutrisiranDrug
Vutrisiran will be administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)]Time frame: Baseline, Month 9
Locations
64 sites in 22 countries. Site status is shown where the registry gives one.
Clinical Trial Site
La Mesa, California
Clinical Trial Site
Aurora, Colorado
Clinical Trial Site
Jacksonville, Florida
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Fairway, Kansas
Clinical Trial Site
Baltimore, Maryland
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
St Louis, Missouri
Clinical Trial Site
New York, New York
Clinical Trial Site
Chapel Hill, North Carolina
Clinical Trial Site
Columbus, Ohio
Clinical Trial Site
Portland, Oregon
Clinical Trial Site
Philadelphia, Pennsylvania
Clinical Trial Site
Dallas, Texas
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Northmead, New South Wales, Australia
Clinical Trial Site
Brisbane, Queensland, Australia
Clinical Trial Site
Melbourne, Victoria, Australia
Clinical Trial Site
Brussels, Belgium
Clinical Trial Site
Leuven, Belgium
Clinical Trial Site
Rio de Janeiro, Brazil
Clinical Trial Site
Sofia, Bulgaria
Clinical Trial Site
Montreal, Canada
Clinical Trial Site
Vancouver, Canada
Clinical Trial Site
Nicosia, Cyprus
Clinical Trial Site
Bordeaux, France
Clinical Trial Site
Créteil, France
Clinical Trial Site
Le Kremlin-Bicêtre, France
Clinical Trial Site
Lille, France
Clinical Trial Site
Marseille, France
Clinical Trial Site
Nantes, France
Clinical Trial Site
Heidelberg, Germany
Clinical Trial Site
Mainz, Germany
Clinical Trial Site
Münster, Germany
Clinical Trial Site
Athens, Greece
Clinical Trial Site
Messina, Italy
Clinical Trial Site
Milan, Italy
Clinical Trial Site
Pavia, Italy
Clinical Trial Site
Rome, Italy
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.